Skip to main content

Veloxis Increases Share Capital in Connection with Exercise of Warrants

Written by Customer Service on . Posted in Public Companies.

Company Release no. 20/2019To: NASDAQ Copenhagen A/S                                                      Copenhagen, Denmark, 5 December 2019 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company’s capital has been increased by 306,250 new shares with a nominal value of DKK 0.10 each corresponding to an increase of the share capital with nominally DKK 30,625 as a consequence of the exercise of warrants by former employees of the Company granted under the Company’s warrant program.As a result of the employee’s investment in the Company proceeds to Veloxis Pharmaceuticals A/S from the capital increase amount to DKK 291,291.50.The subscription price for the new shares is DKK 0.86 per share of nominal DKK 0.10 (with regard to 197,917 shares), DKK 1.01 per share of nominal DKK 0.10 (with regard to 97,222 shares), and DKK 2.06 per share of nominal DKK 0.10 (with regard to 11,111 shares).The new shares will be listed on NASDAQ Copenhagen following registration of the capital increase with the Danish Business Authority, upon which the share capital of Veloxis Pharmaceuticals A/S will be DKK 173,974,159.00 divided into shares of DKK 0.10 each.Each share of nominal DKK 0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S.  The new shares give rights to dividend and other rights from the time of registration of the capital increase with the Danish Business Authority. For more information, please contact:
             
About Veloxis PharmaceuticalsVeloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals, Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the Company’s unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs.  The Company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit www.veloxis.com. Attachment2019.12.05 Company Release 20 _Increase in Share Capital

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.